Figure 4.
Kaplan-Meier standardized leukemia free survival curves of three patient groups. Standardized leukemia free survival of RARS-T is shorter than that of ET patients (median survival 74 months vs. 110 months, log rank test: P<0.001). Standardized leukemia free survival of RARS patients was lower than that of ET patients (P<0.001). ET: essential thrombocythemia; RARS: refractory anemia with ring sideroblasts; RARS-T: refractory anemia with ring sideroblasts and marked thrombocytosis.